Системный обзор и мета-анализ эффективности внутрипузырной терапии при мочепузырном болевом синдроме/интерстициальном цистите

##plugins.themes.bootstrap3.article.main##

J. M. Barua
I. Arance
J. C. Angulo
C. R. Riedl
М. Г. Романюк

Анотація

Мочепузырный болевой синдром/интерстициальный цистит (МБС/ИЦ) является хроническим заболеванием, которое характеризуется постоянными позывами к мочеиспусканию и болью. Целью работы было сравнить клиническую эффективность существующих на рынке препаратов для внутрипузырной терапии МБС/ИЦ и оценить их фармакоэкономический эффект. Был проведен поиск в сервисах Pubmed/Medline статей по внутрипузырной терапии МБС/ИЦ. Всего найдено 345 публикаций, из которых 326 были исключены. Проведена статистическая оценка размера эффекта (РЭ) по степени уменьшения симптомов и по количеству пациентов, ответивших на терапию. Окончательный список, состоящий из 19 статей по внутрипузырной терапии МБС/ИЦ, состоял из 5 проспективных контролируемых исследований (КИ), остальные считались неконтролируемыми. Общее количество пациентов, которые вошли в исследование, составляло 801, 228 из которых были в КИ. Среди КИ, самая большая ВЭ как по уменьшению симптоматики, так и по ответу на терапию, наблюдалась для высокомолекулярной гиалуроновой кислоты (ВМ-ГК), с похожими данными в двух неконтролируемых исследованиях. Количество внутрипузырных введений препарата для получения эффекта у пациента составляло 2,67 для полисульфата пентозана и 1,31 для ВМ-ГК, что превосходило все остальные препараты. ВМ-ГК была значительно более выгодной в отношении эффективности затрат, по сравнению с остальными схемами инстилляций. Данный мета-анализ сочетает в себе медицинские и фармакоэкономические аспекты и демонстрирует преимущество высокомолекулярной гиалуроновой кислоты перед другими препаратами для внутрипузырного введения. Прямого сравнения между различными препаратами не было проведено вследствие особенностей дизайна взятых для анализа исследований.

##plugins.themes.bootstrap3.article.details##

Як цитувати
Barua, J. M., Arance, I., Angulo, J. C., Riedl, C. R., & Романюк, М. Г. (2018). Системный обзор и мета-анализ эффективности внутрипузырной терапии при мочепузырном болевом синдроме/интерстициальном цистите. Здоров’я чоловіка, (3), 43–52. https://doi.org/10.30841/2307-5090.3.2018.156851
Номер
Розділ
Лекції та огляди
Біографії авторів

J. M. Barua, Госпіталь короля Георга (BHRUT), Ілфорд, Лондонська школа медицини та стоматології, QMUL, Лондон

Jayanta M. Barua

I. Arance, Університетська клініка Хетафе, Європейський університет Мадрида, Мадрид

Ignacio Arance,

Урологічна служба

J. C. Angulo, Університетська клініка Хетафе, Європейський університет Мадрида, Мадрид

Javier C. Angulo,

Урологічна служба

C. R. Riedl, Landesklinikum Thermenregion, Баден

Claus R. Riedl,

Відділення урології

М. Г. Романюк, Український інститут сексології та андрології

Романюк Максим Григорович,

автор перекладу

Посилання

Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis/bladder pain syndrome: 2008 snapshot. Neurourol Urodyn 28:274–286. https://doi.org/10.1002/nau.20687

Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, Shackelford DL, Stein P, Parsons CL (1996) A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology 48:817–821. https://doi.org/10.1016/S0090-4295(96)00322-6

Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145:732–735. https://doi.org/10.1016/S0022-5347(17)38437-9

Parsons CL (1996) Potassium sensitivity test. Tech Urol 2:171–173.

Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pfluger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCl vs. 0.2 M KCl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol 170:807–809 https://doi.org/10.1097/01.ju.0000081163.46167.82

Daha KL, Riedl CR, Lazar D, Simak R, Pfluger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol 8:1–4. https://doi.org/10.1080/00365590701871518

Madersbacher H, van Ophoven A, van Kerrebroeck PEVA (2013) GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans – a review. Neurourol Urodyn 32:9–18. https://doi.org/10.1002/nau.22256

Von Heyden B, Schmid HP (2000) Intravesical therapy of interstitial cystitis. Urologe A 39:542–544. https://doi.org/10.1007/s001200050406

Rovner E, Propert KJ, Bresinger C, Wein AJ, Foy M, Kirkemo A et al (2000) Treatment used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 26:940–945. https://doi.org/10.1016/S0090-4295(00)00845-1

Burkman RT (2004) Chronic pelvic pain of bladder origin: epidemiology, pathogenesis and quality of life. J Reprod Med 49:225–229.

Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG (2009) Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int 103:910–918. https://doi.org/10.1111/j.1464-410X.2008.08162.x

Parkin J, Shea C, Sant GR (1997) Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis – a practical approach. Urology 49: 105–107. https://doi.org/10.1016/S0090-4295(97)00181-7

Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur Urol 54:65–75. https://doi.org/10.1016/j.eururo.2008.03.086

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

Morales A, Emerson L, Nickel J, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:445–448. https://doi.org/10.1016/S0022-5347(01)65933-0

Riedl C, Engelhardt P, Daha K, Moraskis N, Pfluger H (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J 19:717–721. https://doi.org/10.1007/s00192-007-0515-5

Daha LK, Lazar D, Simak R, Pfluger H (2008) The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with BPS/IC: preliminary results. Int Urogynecol J 19: 987–990. https://doi.org/10.1007/s00192-008-0560-8

Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Erlbaum, Hillsdale.

Lv YS, Zhou HL, Mao HP, Gao R, Wang YD, Xue XY (2012) Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J 23:1715–1720. https://doi.org/10.1007/s00192-012-1802-3

Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of Intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47:393–397. https://doi.org/10.1016/j.eururo.2004.10.022

Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ESC (2012) Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int. Urogynecol J 23:1533–1539. https://doi.org/10.1007/s00192-012-1699-x

Gafni-Kane A, Botros SM, Du H (2013) Measuring the success of combined intravesical dimethylsulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J 24:303–311. https://doi.org/10.1007/s00192-012-1832-x

Cervigni M, Natale F, Nasta L, Padoa A, Lo Voi R, Porru D (2008) A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J 19:943–947. https://doi.org/10.1007/s00192-008-0572-4

Porru D, Cervigni M, Nasta L, Natale F, Lo Voi R, Tinelli C et al (2008) Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. Rev Recent Clin Trials 3:126–129. https://doi.org/10.2174/157488708784223817

Gauruder-Burmester A,Wildt B, Tunn R (2006) Treatment of overactive bladder with sodium chondroitin sulphate. Zentralbl Gynakol 128:336–340. https://doi.org/10.1055/s-2006-933378

Gauruder-Burmester A, Popken G (2009) Follow-up at 24 months after treatment of overactive bladder with 0.2% sodium chondroitin sulfate. Aktuelle Urol 40:355–359. https://doi.org/10.1055/s-0029-1224600

Hazewinkel MH, Stalpers LJA, Dijkgraaf MG, Roovers JWR (2011) Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J 22:725–730. https://doi.org/10.1007/s00192-010-1357-0

Parsons CL (2005) Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65:45–48. https://doi.org/10.1016/j.urology.2004.08.056

Parsons CL, Zupkas P, Proctor J, Koziol J, Franklin A, Giesing D et al (2012) Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med 9:207–212. https://doi.org/10.1111/j.1743-6109.2011.02542.x

Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa R, Usai E (1997) Results of treatment of refractory interstitial cystitis within travesical hyaluronic acid. Urol Int 59:26–29. https://doi.org/10.1159/000283012

Figuereido AB, Palma P, Riccetto C, Hermann V, Dambros M, Capmartin R (2011) Clinical and urodynamic experience with intravesical hyaluronic acid in painful bladder syndrome associated with interstitial cystitis. Actas Urol Esp 35:184–187. https://doi.org/10.1016/j.acuro.2010.09.004

Cervigni M, Natale F, Nasta L, Mako A (2012) Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: longterm treatment results. Int Urogynecol J 23:1187–1192. https://doi.org/10.1007/s00192-012-1742-y

Sorensen RB (1996) Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol 2:16–18. https://doi.org/10.1016/S1569-9056(03)00036-8

Shao Y, Shen ZJ, Rui WB, Zhou WL (2010) Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 75:547–550. https://doi.org/10.1016/j.urology.2009.09.078

Nickel JC, Egerdie B, Steinhoff G, Palmer B, Hanno P (2010) A multicenter, randomized, double-blind, and parallel groups: pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with IC/PBS.Urology 76:804–809. https://doi.org/10.1016/j.urology.2010.03.016

Nickel JC, Hanno P, Kumar K, Thomas H (2012) Effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 79:1220–1224. https://doi.org/10.1016/j.urology.2012.01.059

Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJA (1997) A placebo-controlled study of intravesical pentosane polysulphate for the treatment of interstitial cystitis. Br J Urol 79:168–171. https://doi.org/10.1046/j.1464-410X.1997.03384.x

Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ (2008) Safety and efficacy of the use of intravesical and oral pentosane polysulfate sodium for interstitial cystitis: a randomized doubleblind clinical trial. J Urol 179:177–185. https://doi.org/10.1016/j.juro.2007.08.170

Sairanen J, Leppilahti M, Tammela TLJ, Paananen I, Aaltomaa S, Taari K, Ruutu M (2009) Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on interstitial cystitis? Scand J Urol Nephrol 43:212–219. https://doi.org/10.1080/00365590802671031

Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR (2011) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22: 401–405. https://doi.org/10.1007/s00192-010-1294-y

Lai MC, Kuo YC, Kuo HC (2013) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome. A comparative randomized assessment of different regimens. Int J Urol 20:203–207. https://doi.org/10.1111/j.1442-2042.2012.03135.x

Kallestrup E, Jorgensen S, Nordling J, Hald H (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147. https://doi.org/10.1080/00365590410015876-1

Gupta SK, Pidcock L, Parr NJ (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96:1063–1066. https://doi.org/10.1111/j.1464-410X.2005.05776.x

Steinhoff G (2003) The efficacy of chondroitin sulphate in treating interstitial cystitis. Eur Urol Suppl 2:14–16. https://doi.org/10.1016/S1569-9056(03)00035-6

Nordling J, van Ophoven A (2008) Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung 58:328–335.

Nickel J, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K (2008) A real-life multicenter clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 103:56–60. https://doi.org/10.1111/j.1464-410X.2008.08028.x

Porru D, Leva F, Parmigiani A, Barletta D, Choussos D, Gardella B et al (2011) Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J 23:1193–1199. https://doi.org/10.1007/s00192-011-1546-5

Bade JJ, Mensink HJ, Laseur M (1995) Intravesical treatment of interstitial cystitis with a heparin analogue. Br J Urol 75:260. https://doi.org/10.1111/j.1464-410X.1995.tb07332.x

Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, Wyndaele JJ (2012) Contemporary management of the painful bladder: a systematic review. Eur Urol 61:29–53. https://doi.org/10.1016/j.eururo.2011.07.069

Matsuoka PK, Hadda JM, Pacetta AM, Baracat EC (2012) Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J 23:1147–1153. https://doi.org/10.1007/s00192-012-1686-2